Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies.

It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.

[1][2]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.